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ABSTRACT
Bronchiectasis is a long-neglected disease currently experiencing a surge in interest. It is a highly complex
conditionwith numerous aetiologies, co-morbidities and aheterogeneous disease presentation and clinical
course. The past few years have seenmajor advances in our understanding of the disease, primarily through
large real-life cohort studies. Themain outcomes of interest in bronchiectasis are symptoms, exacerbations,
treatment response, disease progression and death. We are now more able to identify clearly the radio-
logical, clinical, microbiological and inflammatory contributors to these outcomes. Over the past couple of
years, multidimensional scoring systems such as the Bronchiectasis Severity Index have been introduced to
predict disease severity and mortality. Although there are currently no licensed therapies for bronchiecta-
sis, an increasing number of clinical trials are planned or ongoing. While this emerging evidence is awaited,
bronchiectasis guidelineswill continue to be informed largely by real-life evidence fromobservational stud-
ies and patient registries. Key developments in the bronchiectasis field include the establishment of inter-
national disease registries and characterisation of disease phenotypes using cluster analysis and biological
data.
The ‘new age’of bronchiectasis
Bronchiectasis, which is characterised by irreversible widen-
ing of the bronchi and/or branches along with inflammation
and chronic bacterial infection, is a long-neglected disease
currently experiencing a surge in interest (1). The increasing
incidence and prevalence of bronchiectasis, possibly related
to population ageing and/or greater diagnostic awareness, is a
significant concern for healthcare systems in view of the excess
morbidity and mortality (2,3) and high utilisation of healthcare
resources (4).
There are no licensed treatments specifically for bronchiecta-
sis.Most therapies are extrapolated from either chronic obstruc-
tive pulmonary disease (COPD)/asthma (e.g., bronchodilators
and inhaled corticosteroids) or cystic fibrosis (e.g., long-term
antibiotics and mucoactive therapies) (1). At the clinical level,
identifying patients at highest risk of exacerbations or poor qual-
ity of life is important to intensify treatment. Similarly, identi-
fying patients at low risk of unfavourable outcomes is impor-
tant to avoid overuse of antibiotics and promote antimicrobial
stewardship (5). At the research level, many clinical trials have
failed tomeet their primary endpoints because of heterogeneous
treatment responses and the inherent difficulty of identifying
patients likely to respond (6−8). As a result, the concepts of
phenotyping and disease stratification are now of paramount
importance in bronchiectasis and across the spectrum of airway
diseases (9,10).
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Phenotypes and endotypes
The term ‘phenotype’ is defined in general terms as a set of
observable characteristics of an individual resulting from the
interaction of its nature (genetics) and the environment. For
persons with COPD, Han and colleagues have proposed a vari-
ation, which is: ‘a single or combination of disease attributes
that describe differences between individuals with COPD as
they relate to clinically meaningful outcomes (symptoms, exac-
erbations, response to therapy, rate of disease progression, or
death)’ (11). This definition applies equally well to patients
with COPD, bronchiectasis or alpha-1-antitrypsin deficiency
(AATD). In practical terms, phenotype describes aspects of the
patient that influence clinical decision-making (e.g., the need
for close monitoring because of a worse prognosis) or, perhaps
more importantly, describes how a patient should be treated
based on a specific response to a therapy. Phenotypes are clin-
ically useful; for example, a COPD patient with a history of
exacerbations is more likely to be an exacerbator in future and
can thus be classed as an exacerbator phenotype (12). Alter-
natively, a simple clinical phenotype ‘label’ can mask signifi-
cant complexity. Patients may exacerbate for multiple reasons
including eosinophilic or neutrophilic inflammation, immun-
odeficiency, co-morbidity, genetic susceptibility or microbial
dysbiosis among others (9,13). Insight into the underlying biol-
ogy is therefore key to determining how to treat a ‘pheno-
type’. Bronchiectasis phenotypes are currently emerging. The
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ultimate aim of disease stratification studies is to define endo-
types, which are subtypes of a condition defined by distinct func-
tional and pathobiologicalmechanisms. As the pathophysiology
of bronchiectasis continues to be poorly understood, it is not yet
possible to base treatment decisions on endotypes.
Disease characteristics and outcomes in
bronchiectasis
Describing bronchiectasis phenotypes requires integration of
many pieces of information derived from various clinical
domains. Each domain is associated to a greater or lesser degree
with the clinicallymeaningful outcomes of symptoms, exacerba-
tions, response to therapy, rate of disease progression, and death.
Radiology
Radiological findings in bronchiectasis are associated closely
with aetiology, symptoms, exacerbation frequency and risk of
death. Bronchiectasis shows considerable radiological hetero-
geneity. The most common pattern is lower lobe bronchiec-
tasis, which is characteristic of idiopathic bronchiectasis but
may also be associated with COPD, infection or aspiration.
Bronchiectasis of the middle lobes is classically associated with
nontuberculous mycobacteria (NTM) infection or primary
ciliary dyskinesia. Upper lobe bronchiectasis is suggestive of
cystic fibrosis; hence, all patients presenting with upper lobe
predominant disease should be screened for cystic fibrosis.
Central bronchiectasis is less common and is typically a mani-
festation of allergic bronchopulmonary aspergillosis (ABPA) or
tracheobronchomegaly (Mounier-Kuhn syndrome).
In a study from the United Kingdom, more extensive
bronchiectasis in terms of the number of lobes involved or
the presence of cystic bronchiectasis was independently asso-
ciated with severe exacerbations (hazard ratio [HR] 1.48; 95%
confidence interval [CI]: 1.02−2.15), but was not an indepen-
dent predictor of mortality (14). The finding was in agree-
ment with the work of Loebinger and colleagues who showed,
in 91 patients, that the extent of bronchiectasis, severity of
dilation, bronchial wall thickness, mucus plugging, mosaicism
and emphysema were all associated with mortality on univari-
ate analysis; however, none were independently associated with
mortality on multivariate analysis (15).
Microbiology
Microbiology is a major contributor to bronchiectasis pheno-
type. The absence/presence of bacteria and species type influ-
ence patients’ symptomatology, drive a large proportion of exac-
erbations, and are independently associated with an increased
risk of death.
Pseudomonas aeruginosa is the secondmost common organ-
ism isolated in bronchiectasis after Haemophilus influenzae and
has the greatest impact on clinical outcomes. The derivation
and validation study for the Bronchiectasis Severity Index, a
predictive tool that identifies patients at risk of future mor-
tality, hospitalisation and exacerbations, demonstrated a clear
association between bacteriology and exacerbation frequency
(14). The mean number of annual exacerbations increased from
Figure . Impact of microbiology on annual exacerbation frequency in bronchiec-
tasis (). MRSA, Methicillin-resistant S. aureus.
1.29 ± 0.9 in patients without regular bacterial colonisation in
their sputum, to 2.04 ± 1.4 in the presence of some common
respiratory pathogens, to 2.85± 1.5 in the presence of P. aerugi-
nosa (Figure 1). The negative prognostic impact of P. aeruginosa
colonisation was also evident from a meta-analysis in which
data were pooled from 21 observational cohort studies involv-
ing 3683 adult patients with bronchiectasis (16). Compared
to patients without P. aeruginosa colonisation, those with P.
aeruginosa colonisation had a threefold higher risk of mortality
(p < 0.0001), a sevenfold greater risk of hospital admission
(p < 0.0001), an average of one additional exacerbation per
year (p < 0.0001), a FEV1 15% lower than predicted, and
significantly (p < 0.0001) worse quality of life as measured
by the St. George’s Respiratory Questionnaire (Table 1). Most
differences persisted even after adjustment for factors such
as baseline FEV1. Pseudomonas colonisation is by far the
best described phenotype of bronchiectasis. There is also a
degree of evidence suggesting that P. aeruginosa infection
represents an ‘endotype’ since patients have distinct inflam-
matory profiles, with markedly elevated levels of neutrophil
markers such as elastase, myeloperoxidase and matrix metal-
loproteinases (MMP) (17,18). Some studies suggest that sus-
ceptibility to P. aeruginosa may have a genetic basis (19)
or may be related to the production of aberrant blocking
antibodies (20).
Bacteriology in bronchiectasis is becoming increasingly com-
plex. Traditional culture methods are largely being replaced, at
least for research purposes, with the lung microbiome, a tech-
nology that uses next-generation sequencing to produce a DNA
profile of the diverse bacterial communities present in the lung
(21). Data on lung microbiota composition in bronchiectasis is
Table . Outcomes in bronchiectasis patients with versus without Pseudomonas
aeruginosa colonisation: meta-analysis of  observational cohort studies compris-
ing  patients.
Outcome Odds ratio % CI p-value
Mortality . .−. p< .
Hospital admissions . .−. p< .
Outcome Mean diﬀerence % CI p-value
Exacerbations ./year .−. p< .
Quality of life† . points .−. p< .
Constructed using data from ().
†Assessed by the St George’s Respiratory Questionnaire.
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thus far limited but suggest that less bacterial diversity corre-
lates with lower lung function and higher levels of inflammation,
which can be determined bymeasuring neutrophilmarkers such
as MMPs (18). Bronchiectasis patients with dominance of a sin-
gle species, particularly Pseudomonas sp., have been shown to
have worse symptoms and more inflammation than those with
other airway pathogens (22). Determining whether bronchiec-
tasis phenotypes/endotypes can be defined based onmicrobiota
profiles will require larger studies.
Aetiology
An important initial step in managing patients with bronchiec-
tasis is to identify the underlying aetiology. Numerous diseases
can lead to bronchiectasis, and the specific aetiology influences
clinical manifestations and outcomes.
The European Multicentre Bronchiectasis Audit and
Research Collaboration (EMBARC) registry is a European
Respiratory Society initiative aimed at collecting more data
through a prospective, pan-European observational study of
patients with bronchiectasis (23). The study received central
ethical approval in January 2015 and, as of September 2016, had
participants from 232 registered centres in 40 countries. The
registry currently holds data on more than 4000 patients and
aims to recruit 10,000 patients by March 2020.
The most recent data from the EMBARC registry, which was
presented at the European Respiratory Society (ERS) Congress
2016, reported on 2031 patients from 23 European countries
(24). Mean age of patients with bronchiectasis in Europe was
63 years, and 58% were women (24). The most common aeti-
ology was idiopathic bronchiectasis (39%), followed by post-
infective bronchiectasis (27%). A relevant proportion of patients
had diagnoses requiring a specific treatment, including immun-
odeficiency diseases, ABPA,NTM infection andAATD. For best
outcomes, such patients must be identified from the general
bronchiectasis population and treated appropriately (e.g., cor-
ticosteroids with or without antifungal treatment for ABPA).
The demographic and disease-related characteristics of the pop-
ulation were similar to other cohorts reported from Europe
(25,26). In contrast, there are marked differences in the pre-
sentation of bronchiectasis internationally. For example, the
bronchiectasis population described in Guangzhou, China, had
a similar gender balance (62% female) but was considerably
younger (mean age 44 years) than the European cohorts. Aeti-
ology was mainly idiopathic (46%), followed by post-infectious
(27%), and immunodeficiency (9%) (27). The EMBARC reg-
istry has recently expanded to include non-European centres
including India. First data from the Indian registry were pre-
sented at ERS 2016. In India (n = 552), the bronchiectasis pop-
ulation was 63% male and had a mean age of 51 years. The
most frequent aetiologies were post-tuberculosis bronchiectasis
(29%), idiopathic bronchiectasis (27%) and post-infective (non-
TB) bronchiectasis (21%). A different pattern of bronchiecta-
sis again is observed in the United States. First analysis of the
United States Bronchiectasis Research Registry (n= 1826) indi-
cated a mean age similar to European cohorts (64 years), but
with greater female predominance (79%) and a high proportion
of patients (63%) with a history of NTM infection or NTM iso-
lated at the time of baseline evaluation into the registry (28).
Insight into local patterns of bronchiectasis is of consider-
able clinical importance due to the direct influence of aetiology
on treatment decisions. For example, in Europe, about 20% of
bronchiectasis patients are treated withmacrolide antibiotics. In
the United States, macrolide use would need to be approached
with extreme caution to avoid inducingNTM resistance. Demo-
graphic and clinical heterogeneity between bronchiectasis pop-
ulations also influence the ability to perform clinical trials and
the extent to which results from any given region would apply
elsewhere. Observational studies and patient registries represent
the actual population in a given location and are thus essential
in terms of understanding the true complexity and heterogene-
ity of this disease.
Understanding prognosis in bronchiectasis
Multidimensional scoring systems developed for COPD, such as
the BODE (Body mass index [BMI], airflow Obstruction, Dys-
pnea and Exercise capacity) Index and GOLD (Global initia-
tive for chronic Obstructive Lung Disease) classification system,
have increased our understanding of disease heterogeneity. In
the past few years, similar grading systems have also been intro-
duced in bronchiectasis.
As mentioned above, the Bronchiectasis Severity Index was
developed as a tool to determine disease severity by identify-
ing independent risk factors for mortality, exacerbations, hos-
pitalisations, and quality of life (14). The scoring system was
derived initially using data from 608 patients enrolled in a
prospective cohort study (Edinburgh, UK). The instrument was
subsequently validated in independent patient cohorts from
Dundee,UK (n= 218), Leuven, Belgium (n= 253),Monza, Italy
(n = 105) and Newcastle, UK (n = 126). The Bronchiectasis
Severity Index comprises eight factors: age; BMI; FEV1; hos-
pital admissions; exacerbations; breathlessness; P. aeruginosa
colonisation or colonisation with other bacteria; and radiologi-
cal severity. Scores range from aminimumof 0 to amaximumof
25. Based on disease severity, it is possible to describe bronchiec-
tasis phenotypes that relate to clinically relevant outcomes.
Elsewhere, a Spanish group has developed a multidimen-
sional scoring system to predict mortality in patients with
bronchiectasis (29). Data used to construct the FACED score
were derived from a retrospective cohort study of 819 patients
with bronchiectasis diagnosed by high-resolution computed
tomography (CT); 397 patients were used to construct the score,
and the remaining 422 patients were used to validate the score.
The system incorporates five dichotomised variables associated
with poor outcomes: FEV1 (F, cut-off 50%, maximum value 2
points); age (A, cut-off 70 years, 2 points); colonisation with
P. aeruginosa (C, yes/no, 1 point); radiological extension (E,
number of affected lobes, cut-off 2 lobes, 1 point); and dyspnoea
(D, cut-off grade II on the Medical Research Council scale, 1
point). Patients with higher scores (5–7 points) have a signif-
icantly higher risk of mortality compared to those with lower
scores.
A series of large studies comparing these scoring systems
confirmed that, while their ability to predict mortality may
be similar, there are also some important differences. The
Bronchiectasis Severity Index accurately reflects disease sever-
ity and disease impact such as exacerbation frequency, hospital
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admissions, quality of life, exercise capacity and symptoms such
as cough (30,31). In contrast, the FACED scoring system lacks
this same ability, possibly because it is heavily weighted by age.
Two points are awarded for age, with the cut-off being 70 years.
Thus, in patients aged < 70 years (the majority of bronchiecta-
sis populations), all other factors must be present for a patient to
be classified as high risk.Many patients with high disease impact
are thus classified asmild ormoderate risk. The relevance of this
difference between the scoring systems is illustrated by exam-
ining patients receiving lung transplantation for bronchiecta-
sis, the classic example of a patient subset regarded univer-
sally as ‘severe’. In a recent series of 34 patients who underwent
lung transplantation for bronchiectasis (32), the Bronchiecta-
sis Severity Index identified 100% of patients as severe, whereas
more than half of patients were identified as mild or moderate
by the FACED score.
Thus, for optimal result with these scoring systems, each
instrument must be used solely for its intended purpose. The
Bronchiectasis Severity Index has been designed to predict
severity and quality of life across a range of outcomes, whereas
the FACED score was developed to predict mortality alone.
Multidimensional clustering
Multidimensional clustering has been proven to be a highly suc-
cessful approach to understanding heterogeneity in COPD and
asthma (33,34). The method involves applying complex statisti-
cal methods to a large data set to determine which demographic
and clinical variables are inter-related, and then using these
‘clusters’ to describe phenotypes. To this end, a secondary anal-
ysis was conducted of five European databases involving 1145
prospectively enrolled adult patients with bronchiectasis (35).
Principal component and cluster analyses were performed using
demographics, co-morbidities, and clinical, radiological, func-
tional andmicrobiological variables collected frompatients dur-
ing the stable state. Data on exacerbations, hospitalisations and
mortality recorded during 3-year follow-up were also included
in the analysis. Four bronchiectasis phenotypes were identified
based on colonisation status and daily sputum production:
 severe Pseudomonas infection (16%);
 other chronic infections (e.g. Haemophilus) (24%);
 daily sputum production without colonisation (33%);
 dry bronchiectasis (27%).
During follow-up, patients in the four clusters showed
significant differences in terms of their quality of life, exacer-
bations, hospitalisations and mortality. There was also clear evi-
dence of increased neutrophilic inflammation in the infection-
driven clusters (35).
While the analysis has a certain degree of value in terms of
informing future research (e.g., focused treatment by pheno-
type), it can also be criticised for not extending current knowl-
edge (5). Similar analyses conducted in other world regions have
provided some interesting variations.
In China, hierarchical cluster analysis was performed using
demographic data, as well as clinical variables relating to lung
function, sputum bacteriology, aetiology, radiology, disease
severity, quality of life, cough scale, capsaicin sensitivity, exer-
cise tolerance, health care use and frequency of exacerbations in
148 patients with bronchiectasis (36). Four distinct clusters were
described:
 mild and idiopathic bronchiectasis in young patients;
 severe patients with post-infective bronchiectasis and
P. aeruginosa;
 late onset severe idiopathic bronchiectasis;
 elderly patients with moderate disease.
The only consistency between the Chinese and Euro-
pean analyses was the Pseudomonas phenotype, which is
not surprising given the demographic and aetiological dif-
ferences in bronchiectasis populations between these two
regions. The relatively small patient sample in the Chinese
study may also have contributed to variation in the proposed
phenotypes.
Cluster analysis was also performed in Spain using data from
the same retrospective cohort study used to derive the FACED
score (37). The available population (n = 468) was 58% female
with a mean age of 63 years. Significant variables used for this
analysis included age, gender, BMI, smoking habit, dyspnoea,
macroscopic appearance of sputum, number of exacerbations,
chronic colonisation with P. aeruginosa, FEV1, number of pul-
monary lobes affected, idiopathic bronchiectasis and associ-
ated COPD. Once again, four distinct phenotypes with different
prognoses were identified:
 young women with mild disease;
 overweight elderly women with mild bronchiectasis;
 elderly men with severe disease, chronic infection (mainly
with P. aeruginosa), airflow obstruction and exacerbations;
 elderly patients with ‘severe’ disease but infrequent exacer-
bations.
The take-home message to emerge from examining
these three separate analyses, which incorporated different
approaches (i.e., variables considered significant for analysis)
but used the same statistical method, is that the phenotypes
proposed by each group may or may not be true phenotypes.
Only the P. aeruginosa infection, frequently exacerbating phe-
notype was consistent across all analyses and, indeed, is the
most robust phenotype identified to date in bronchiectasis (16).
A challenge for future may be to look beyond phenotypes and
aim towards identifying endotypes.
Co-morbidity
On account of the relatively advanced average age of bronchiec-
tasis patients in Europe and other Western regions (e.g.
60−70 years), the presence of co-morbidities apart from the
underlying aetiological disease/s is common. In a multicentre
cohort analysis of 986 patients with bronchiectasis from four
European centres, the average patient had four co-morbid con-
ditions (38). An independent relationship was demonstrated
between the number of co-morbidities and long-term mor-
tality. Co-morbidities independently associated with mortality
were malignant disease (including haematological malignancy),
COPD, cognitive impairment, inflammatory bowel disease, liver
disease, connective tissue diseases (e.g. rheumatoid arthritis),
iron deficiency anaemia, diabetes, asthma, pulmonary hyper-
tension, peripheral vascular disease and ischaemic heart dis-
ease. Other groups have been hinting at these relationships for
some time, with individual studies showing the importance of
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co-morbid COPD (39), asthma (40) and cardiovascular diseases
(41) on the risk of poorer outcomes.
The study of McDonnell and co-workers is particularly rel-
evant for having been first to demonstrate the link between co-
morbidities and aetiologies, which were then used to construct
the Bronchiectasis Aetiology and Co-morbidity Index (BACI)
(38). The BACI predicted 5-year mortality (p < 0.0001), hospi-
tal admissions (p< 0.0001), exacerbations (p = 0.03) and qual-
ity of life (p < 0.0008) for all strata of bronchiectasis severity as
assessed by the Bronchiectasis Severity Index (14). P. aeruginosa
colonisation was also linked to co-morbidities. Co-morbidities
predicted mortality risk with a higher accuracy than markers
of bronchiectasis severity, emphasising the importance of incor-
porating aetiologies and co-morbidities into multidimensional
phenotyping of patients with bronchiectasis.
Inflammation and elastin breakdown
COPD, AATD and bronchiectasis all share in common the pres-
ence of neutrophilic inflammation, although each condition is
characterised to a differing degree by bacterial infection. In
bronchiectasis, higher airway bacterial loads are associated with
airway and systemic inflammation and greater risk of exacer-
bation (42). Lungs of bronchiectasis patients show active prote-
olytic damage similar to that observed in COPDwith high levels
of neutrophil elastase, MMPs and other markers. Although the
damagemay be ameliorated to some degree with antibiotic ther-
apy, it tends to return soon after the antibiotics are discontinued
(42).
Neutrophil elastase, a serine protease released from primary
neutrophil granules, is linked to disease severity in bronchiec-
tasis. Tsang and colleagues showed a clear association between
elastase in sputum and extent of bronchiectasis and FEV1
(43), while Goeminne and co-workers showed that elastase
was responsible for 82% of the total gelatinolytic activity of
bronchiectasis sputum (44). Elastin breakdown in patients with
bronchiectasis is evident in lung histology early in the disease
and increases with worsening severity. Proteolytic breakdown
can bemeasured indirectly (serumdesmosine) through the gen-
eration of unique cross linking amino acids that are released
when elastin is degraded. Recent data in 386 patients from the
United Kingdom showed that elevated sputum neutrophil elas-
tase activity was associated with shorter time to next exacer-
bation, more rapid lung function decline, higher risk of hospi-
talisation, and mortality (45). Desmosine was also significantly
associated with the risk of severe exacerbations (HR 2.7; 95%
CI: 1.42−5.29; p = 0.003). Neutrophilic inflammation is thus
a key driver of disease progression in bronchiectasis. Patients
with accelerated elastin breakdown may represent a bronchiec-
tasis endotype (45).
Treatment of bronchiectasis
It remains uncertain, at present, whether bronchiectasis pheno-
types described to date will be able to inform treatment. Data
regarding bronchiectasis treatment, and more so phenotype-
directed treatment, are limited. Primary goals of treatment con-
tinue to be to reduce exacerbations and improve quality of life.
Bronchiectasis management is expected to undergo consider-
able change over the next 5 years as the results of ongoing clin-
ical trials (e.g., multiple antibiotics, anti-inflammatory agents,
extrapolation of therapies used in cystic fibrosis) become avail-
able. Nevertheless, we remain without robust evidence for many
widely used treatments. A lack of research funding and the
‘orphan nature’ of the disease, together with heterogeneity in
aetiology and presentation, are likely to preclude the design and
conduct of large-scale randomised controlled trials for many
therapies. For the foreseeable future, it is expected that core
knowledge will continue to come from real-life clinical data and
registries. Treatment will remain largely empirical using best
clinical judgement.
A consensus statement from the EMBARC Clinical Research
Collaboration has identified key research priorities in the field
of bronchiectasis (46). The 55 recommendations provide a
roadmap for improving our understanding of the disease and
providing better outcomes for patients.
Conclusions
Bronchiectasis is a rapidly developing field. Although disease
phenotyping is in its infancy, analyses performed to date sug-
gest enormous heterogeneity in disease severity and presenta-
tion as well as potential to identify populations with greater
likelihood of treatment response and varying prognoses. Many
patients with bronchiectasis experience long diagnostic delays,
and underdiagnosis continues to be common. While new ther-
apies are welcomed, their introduction will bring the associated
challenge of identifying patients likely to gain the most bene-
fit. Most potential new therapies are antibiotic-related and thus
carry the risk of antibiotic resistance. Registries, networks and
greater collaborative efforts are essential elements of generating
real-life data to inform clinical guidelines.
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